EVOLUS INC (EOLS) — insider trading
Health Care · NASDAQ
EVOLUS INC (EOLS) has 22 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 22 (latest 2026-03-20).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-20 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Open-market sale | 13,669 | $4.75 | $64.9K | Form 4 |
| 2026-03-20 | Avelar Rui | Officer (See Remarks) | Open-market sale | 3,119 | $4.75 | $14.8K | Form 4 |
| 2026-03-17 | Avelar Rui | Officer (See Remarks) | Open-market sale | 29,996 | $4.89 | $146.6K | Form 4 |
| 2026-03-17 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Open-market sale | 116,720 | $4.89 | $570.6K | Form 4 |
| 2026-03-16 | Avelar Rui | Officer (See Remarks) | Option exercise / conversion (derivative) | 8,804 | $0.00 | $0 | Form 4 |
| 2026-03-16 | Avelar Rui | Officer (See Remarks) | Option exercise / conversion | 8,804 | $0.00 | $0 | Form 4 |
| 2026-03-16 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Option exercise / conversion (derivative) | 67,489 | $0.00 | $0 | Form 4 |
| 2026-03-16 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Option exercise / conversion | 67,489 | $0.00 | $0 | Form 4 |
| 2026-02-17 | GILL DAVID N | Director | Grant / award / vesting | 45,559 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Avelar Rui | Officer (See Remarks) | Grant / award / vesting (derivative) | 138,649 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Avelar Rui | Officer (See Remarks) | Grant / award / vesting (derivative) | 94,913 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Avelar Rui | Officer (See Remarks) | Grant / award / vesting | 94,913 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Malik Vikram | Director | Grant / award / vesting | 45,559 | $0.00 | $0 | Form 4 |
| 2026-02-17 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Grant / award / vesting (derivative) | 457,541 | $0.00 | $0 | Form 4 |
| 2026-02-17 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Grant / award / vesting (derivative) | 626,424 | $0.00 | $0 | Form 4 |
| 2026-02-17 | MOATAZEDI DAVID | Director, Officer (See Remarks) | Grant / award / vesting | 313,212 | $0.00 | $0 | Form 4 |
| 2026-02-17 | White Albert G III | Director | Grant / award / vesting | 45,559 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Mitchell Tatjana | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 177,471 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Mitchell Tatjana | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 121,489 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Mitchell Tatjana | Officer (Chief Financial Officer) | Grant / award / vesting | 121,489 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Stewart Brady | Director | Grant / award / vesting | 45,559 | $0.00 | $0 | Form 4 |
| 2026-02-17 | Parschauer Karah Herdman | Director | Grant / award / vesting | 45,559 | $0.00 | $0 | Form 4 |
Ask the chat about EOLS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: EVOLUS INC (EOLS).
Last updated 2026-03-20 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.